Drugs derived from phage display

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

(2013) M Peeters et al.   BRITISH JOURNAL OF CANCER

VEGFA and tumour angiogenesis

(2013) L. Claesson-Welsh et al.   JOURNAL OF INTERNAL MEDICINE

Which are the antibodies to watch in 2013?

(2013) Janice M. Reichert   mAbs

Molecular Determinants of Epidermal Growth Factor Binding: A Molecular Dynamics Study

(2013) Jeffrey M. Sanders et al.   PLoS One

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

(2012) M. M. Eatock et al.   ANNALS OF ONCOLOGY

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of Anti-Infectives Using Phage Display: Biological Agents against Bacteria, Viruses, and Parasites

(2012) Johnny X. Huang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

(2012) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Antibody Phage Display Libraries: Contributions to Oncology

(2012) Carmela Dantas-Barbosa et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Which are the antibodies to watch in 2012?

(2012) Janice M. Reichert   mAbs

Peptibodies: A flexible alternative format to antibodies

(2012) Grant Shimamoto et al.   mAbs

Solubility evaluation of murine hybridoma antibodies

(2012) Stacey Spencer et al.   mAbs

Vascular Endothelial Growth Factor A in Intraocular Vascular Disease

(2012) Joan W. Miller et al.   OPHTHALMOLOGY

Acute and Impaired Wound Healing

(2012) Tatiana N. Demidova-Rice et al.   Advances in Skin & Wound Care

Licensure of vaccines using the Animal Rule

(2012) Drusilla L Burns   Current Opinion in Virology

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

(2012) William Stohl   Current Rheumatology Reports

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability

(2011) Greg P. Conley et al.   BIOTECHNOLOGY AND BIOENGINEERING

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

(2011) Rodrigo Dienstmann et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Beyond natural antibodies: the power of in vitro display technologies

(2011) Andrew R M Bradbury et al.   NATURE BIOTECHNOLOGY

Antibodies against Anthrax: Mechanisms of Action and Clinical Applications

(2011) Jeffrey W. Froude II et al.   Toxins

Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma

(2010) Kusumam Joseph et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Phage display as a powerful tool to engineer protease inhibitors

(2010) Marie-Louise Zani et al.   BIOCHIMIE

Phage display: Concept, innovations, applications and future

(2010) Jyoti Pande et al.   BIOTECHNOLOGY ADVANCES

Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications

(2010) Kathlynn Brown   CURRENT PHARMACEUTICAL DESIGN

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Raxibacumab

(2010) Sohini Mazumdar   mAbs

Structure-based engineering of a monoclonal antibody for improved solubility

(2010) S.-J. Wu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

(2009) Annett M. Jacobi et al.   ARTHRITIS AND RHEUMATISM

Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis

(2009) Laetitia Devy et al.   CANCER RESEARCH

Engineered protein scaffolds as next-generation antibody therapeutics

(2009) Michaela Gebauer et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability

(2009) Jonathan A Bernstein et al.   Expert Review of Clinical Immunology

An improved manufacturing process for Xyntha/ReFacto AF

(2009) B. KELLEY et al.   HAEMOPHILIA

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Raxibacumab for the Treatment of Inhalational Anthrax

(2009) Thi-Sau Migone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cross-Interaction Chromatography: A Rapid Method to Identify Highly Soluble Monoclonal Antibody Candidates

(2009) Steven A. Jacobs et al.   PHARMACEUTICAL RESEARCH

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity Antibodies

(2008) Christine Rothe et al.   JOURNAL OF MOLECULAR BIOLOGY

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET